Dr. Port is the author of a variety of publications on the role of sentinel lymph node biopsy in breast cancer, the role of MRI in patients at high risk for breast cancer, and she has received a Komen Foundation Grant investigating the role of PET scanning in breast cancer. She recently completed an NCI funded clinical trial investigating the effects of the COX2 inhibitor, Celebrex, on breast cancer tissue.
Dr. Port is a member of many professional organizations including the Society of Surgical Oncology, the American Society of Breast Diseases, the American Society of Breast Surgeons, and the American College of Surgeons Oncology Group.